

## **Tristel plc**

## ("Tristel", the "Company" or the "Group")

## **Exercise of Share Options and Total Voting Rights**

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products utilising proprietary chlorine dioxide technology announces that it has issued and allotted a total of 29,950 new ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares") following the exercise of options by employees of the Group.

Application has been made to the London Stock Exchange for the 29,950 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 22 April 2022.

After Admission, the total number of Ordinary Shares in issue will be 47,224,993 and the total number of voting rights will therefore be 47,224,993. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

www.tristel.com

Tel: 01638 721 500

Paul Swinney, Chief Executive

Liz Dixon, Finance Director

**Tristel plc** 

## finnCap Limited – Nominated Adviser and Broker

Geoff Nash / Charles Beeson, Corporate Finance

Tel: 020 7220 0500

Alice Lane, Corporate Broking

Walbrook PR Ltd

Paul McManus

Lianne Cawthorne

tristel@walbrookpr.com Tel: 020 7933 8780

Mob: 07980 541 893

Mob: 07584 391 303

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.